Company news

Share this article:
A spokesperson for GlaxoSmithKline told reporters that the company will make an announcement to US employees tomorrow about a reorganization, prompting press speculation about cuts to US-based sales forces.

Genzyme and Osiris Therapeutics have announced a partnership to develop and commercialize Prochymal and Chondrogen, two late-stage adult stem cell treatments. Osiris will commercialize the two treatments in the US and Canada, with Genzyme marketing the treatments in other countries.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions